Our finding that the pharmacological inhibition of prefrontal GluN2A-containing NMDA receptors may produce both antidepressant-like effects and schizophrenia-like behaviors aligns with clinical observations of ketamine, which can induce psychotomimetic side effects when used to treat major depressive disorder. This evidence concerns the gene GRIN2A and schizophrenia.